David Happel insider trades

Open-market stock purchases and sales by David Happel, President & CEO at Sagimet Biosciences Inc, from SEC Form 4 filings since Nov 25, 2014.

Track record: 100% of 3 scored buys are up 5% or more since purchase, averaging +87%.

Recent trades

DateStockTradeValue
May 28, 2026SGMT Sagimet Biosciences IncBought (not open market)—
Feb 19, 2026SGMT Sagimet Biosciences IncBought (not open market)—
Feb 19, 2026SGMT Sagimet Biosciences IncBought (not open market)—
Feb 10, 2026SGMT Sagimet Biosciences IncSold$64.9K

Companies traded

  • SGMT Sagimet Biosciences Inc: 3 buys, 2 sales, last May 28, 2026
  • HZNP Horizon Pharma plc: other filings, last Oct 25, 2017
  • RPTP Raptor Pharmaceutical Corp: other filings, last Oct 25, 2016

Get free alerts when David Happel files a new trade →